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Abstract 25 
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There is an inverse correlation between human birthweight and umbilical venous angiotensin 26 
II (AngII) concentrations. Oxidative stress and increased prorenin receptor (PRR) both 27 
enhance the cleavage of angiotensin I from angiotensinogen (AGT).  Pre-eclampsia, a 28 
hypertensive disorder of pregnancy, manifests as high blood pressure and proteinuria, and is a 29 
state of increased oxidative stress.  30 
Objectives, study design and main outcome measures: Hypothesis: Pre-eclampsia will be 31 
associated with increased placental expression of components of the renin-angiotensin 32 
system, which could result in reduced infant birthweight. Biopsies were taken 1cm from the 33 
placental edge from 27 normotensive controls and 23 pre-eclamptic White European women. 34 
Immunohistochemistry was performed for AGT, PRR, glutathione peroxidase 3 (GPx3) and 35 
the AT1R and AT2R AngII receptors. Protein expression was semi-quantitatively assessed 36 
(H-score).  37 
Results: AT1R expression was significantly increased in pre-eclamptic placentae, and 38 
negatively correlated with birthweight (r = - 0.529, P = 0.009). AT1R expression was also 39 
negatively correlated with GPx3 expression overall (r = -0.647; P = 0.005). AT2R expression 40 
positively correlated with AGT (r = 0.615, P = 0.002) in the pre-eclamptic placentae only. 41 
Conclusions: The raised AT1R expression in pre-eclampsia, together with inadequate 42 
antioxidant protection, possibly through lower GPx activity, might enhance the 43 
vasoconstrictor effect of locally-generated AngII, contributing to the restricted fetal growth 44 
characteristic of pre-eclampsia. Conversely, the AT2R:AGT association within the pre-45 
eclamptic placenta may provide a compensatory mechanism.  46 
 47 
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Pre-eclampsia is a hypertensive disorder of pregnancy that occurs in ~3% of all pregnancies. 51 
This disease, which manifests as high blood pressure and proteinuria, is probably mediated 52 
by endothelial damage and may affect multiple systems of the body and contribute to adverse 53 
pregnancy outcomes including maternal death, preterm birth, intrauterine growth restriction 54 
(IUGR) and fetal death [1]. Together with other hypertensive disorders of pregnancy, pre-55 
eclampsia is responsible for at least 60,000 maternal deaths each year [2] and increases 56 
perinatal mortality 5-fold [3]. Placental and maternal systemic oxidative stress are 57 
components of the syndrome [4, 5] and contribute to a generalised maternal systemic 58 
inflammatory activation [6]. Placental ischemia-reperfusion injury has been implicated in 59 
excessive production of reactive oxygen species (ROS), which could cause release of 60 
placental factors that mediate the inflammatory responses [7]. We have recently shown that 61 
placental antioxidant glutathione peroxidise (GPx) activity and expression are reduced in pre-62 
eclampsia [8].  63 
 64 
The renin–angiotensin system (RAS) is known to be an important regulator of blood pressure, 65 
sodium and fluid homeostasis. In non-pregnant models, enhanced RAS activity causes 66 
hypertension [9], salt retention [10], and hyperaldosteronism [11]. Although the exact 67 
mechanism of pre-eclampsia remains unclear, it appears that angiotensinogen (AGT) could 68 
play critical roles in its development [12]. AGT is the only renin substrate, and is thus a 69 
major molecule in the RAS. Prorenin (PR) is the biosynthetic precursor of renin, the structure 70 
of which includes a peptide which obstructs the access of AGT to the active site of renin, 71 
which binds to its receptor, prorenin receptor (PRR or ATPase H+ transporting lysosomal 72 
accessory protein 2; ATP6AP2) [13]. Oxidative stress and increased PRR expression both 73 
enhance the cleavage of angiotensin I (Ang I) from AGT.  Hypoxaemia in the chronically-74 
cannulated fetal lamb was associated with a doubling of circulating angiotensin II (AngII) 75 
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concentrations [14], and umbilical venous Ang II concentrations are higher in smaller babies 76 
[15, 16]. AngII exerts part of its vasoconstrictor effect through the generation of ROS [17]. 77 
 78 
Ang II exerts a majority of its effects through two major angiotensin receptors: AT1R and 79 
AT2R. These highly conserved seven-transmembrane G-protein–coupled receptors share a 80 
34% sequence identity and have comparable affinities for Ang II [18]. Most of the actions of 81 
Ang II, including vasoconstriction and stimulation of aldosterone synthesis, angiogenesis and 82 
cell growth are mediated by the AT1R [17]. The AT2R is implicated in apoptosis, reduction 83 
in endothelial cell growth and migration, and vasodilation in the adult, the reduction in 84 
neointima formation after vascular injury [19-23], although it is usually expressed at low 85 
density. However, expression is much higher during fetal life, where it may counterbalance 86 
the effects of the AT1Rs during fetal development. Endothelial cell growth, migration, 87 
angiogenesis and apoptosis allowing spiral artery remodelling are all central to placentation.  88 
 89 
In the placenta, an intrinsic angiotensin-generating system has been well documented based 90 
on the presence of major RAS components including renin, AGT, angiotensin-converting 91 
enzyme (ACE), and Ang II as well as its receptor subtypes [24-26]. The conversion of Ang I 92 
to Ang II by ACE in the feto-placental bed leads to a potent vasoconstrictor activity in the 93 
feto-placental circulation [27, 28]. Placental trophoblasts are particularly AT1R rich [29]. A 94 
functioning placental RAS appears necessary for an uncomplicated pregnancy [30]. There is 95 
an inverse correlation between human birthweight and umbilical venous AngII concentrations 96 
[31]. An elevated fetal plasma renin activity [32] and fetal Ang II concentration [16] have 97 
also been reported in IUGR. However, there is controversy about the expression of placental 98 
angiotensin receptors in pre-eclampsia.  99 
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These early studies did not examine the placental RAS in detail. A recent paper has reported 100 
on placental expression of PRR and AGT in normal term pregnancy [33], but these have not 101 
been described in relation to pre-eclampsia. We thus hypothesised that pre-eclampsia, a state 102 
of increased oxidative stress, will be associated with increased placental expression of 103 
components of the RAS, which could result in reduced infant birthweight. 104 
 105 
 106 
 107 
 108 
 109 
 110 
 111 
 112 
 113 
 114 
 115 
 116 
 117 
 118 
 119 
 120 
 121 
 122 
 123 
 124 
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Methods 125 
Subjects: 126 
The study population consisted of White European women who had either a normotensive or 127 
pre-eclamptic pregnancy as previously described [4]. The investigations were approved by 128 
the Nottingham Hospital Ethics Committee and written, informed consent was obtained from 129 
each subject. Cases were defined on admission with a clinical diagnosis of pre-eclampsia, 130 
defined using the International Study for the Study of Hypertension in Pregnancy guidelines 131 
[34]. Medical and obstetric histories, including delivery data, were obtained for each woman. 132 
The birthweight centile for each baby was computed, correcting for gestation age, sex, 133 
maternal parity and body mass index (BMI) [35]. 134 
 135 
Sample collection: 136 
Full depth placental biopsies were taken 1cm from the placental edge from 27 normotensive 137 
and 23 pre-eclamptic women, avoiding placental infarcts. Tissues were taken within 10 min 138 
of delivery, membranes removed and tissue washed in ice cold 1× PBS to remove maternal 139 
blood contamination. Biopsies were formalin fixed and wax-embedded for 140 
immunohistochemical analysis. 141 
 142 
Immunohistochemistry: 143 
Immunohistochemical staining was performed on serial sections as previously described [8] 144 
using the Dako Envision™ visualization system (Dako, Ely, UK).  Table 1 provides further 145 
details on antibody dilutions used, which were optimised by performing a dilution series for 146 
each antibody. The heat-induced epitope retrieval was achieved by heating in a citrate buffer 147 
(pH 6.0) using a microwave oven for 15 min. A negative control was performed for each test 148 
section by incubation with mouse or rabbit IgG as appropriate. Sections were dehydrated and 149 
7 
 
cleaned in ascending concentrations of alcohol and xylene before coverslips were mounted 150 
(DPX mountant, BDH). Protein expression was semi-quantitatively assessed (H-score) at 151 
x200 magnification (Nikon Eclipse II microscope) by two blinded observers as described 152 
previously [36]. Between-observer agreement for H-scoring was excellent (kappa 0.97). 153 
 154 
Maternal plasma thiobarbituric acid reactive substances (TBARS) concentrations were 155 
measured as a global measure of oxidative stress; plasma total GPx activity and placental 156 
GPx3 protein expression were measured as indices of specific antioxidant activity. These data 157 
have been previously reported [4]. 158 
 159 
Statistical analysis 160 
All tests were performed using SPSS for Windows version 19.0. Summary data are presented 161 
as median (interquartile range) as appropriate for their distribution after testing for normality 162 
using the Kolmogorov-Smirnov test. Mann–Whitney U-tests were used to test differences 163 
between normotensive and pre-eclampsia groups. Spearman’s Rho correlation and Kendall’s 164 
Tau ranking tests were also conducted as appropriate. The null hypothesis was rejected where 165 
P < 0.05.  166 
 167 
 168 
 169 
 170 
 171 
 172 
 173 
 174 
8 
 
Results 175 
All women conceived naturally and carried singleton pregnancies. The demographic, 176 
obstetric and pregnancy data of the 50 women (27 normotensive, 23 pre-eclampsia) who 177 
participated in the study are shown in Table 2. The complete and detailed data have been 178 
previously published [4]. In summary, women in the normotensive group gave birth without 179 
developing hypertension or proteinuria, to infants weighing >2500 g, delivered at 37 weeks 180 
or later. Overall, the pre-eclamptic women all had moderate to severe disease and had lower 181 
gestational ages at delivery than the control group (P < 0.05; Table 2). No pre-eclamptic 182 
woman had Haemolysis Elevated Liver enzymes, and Low Platelet count (HELLP). All 183 
neonates from both pregnancy groups survived.  184 
 185 
All components of the RAS that were measured in this study were found to be expressed in 186 
placental tissue, mainly localised to the villous syncytiotrophoblast, with some stromal 187 
staining (Figure 1). Table 3 summarises the staining intensity of AGT, PRR, AT1R, AT2R 188 
and GPx3 in placentae from normotensive and pre-eclamptic women. AT1R expression was 189 
significantly increased in pre-eclamptic compared to normotensive placentae (P = 0.032; 190 
Table 3); all other RAS components were similarly expressed in both groups. Placental GPx3 191 
expression (Table 3) and maternal plasma total GPx activity [4, 8] were significantly reduced 192 
in pre-eclampsia while TBARS were highly significantly increased (1.2 [0.6, 1.6] compared 193 
to 0.45 [0.2, 0.8] mol/l (P < 0.001)[4].  194 
 195 
A negative association was observed between AT1R and birthweight in the pre-eclamptic 196 
group (Figure 2; r = - 0.529, P=0.009) but not in the normotensive group (P > 0.5).  A 197 
significant inverse correlation was also found overall between placental AT1R and GPx3 198 
protein expression (Figure 3; r = 0.634; P = 0.006). AT2R expression was found to be 199 
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positively related to AGT in pre-eclampsia (r = 0.615, P = 0.002), but not control, placentae 200 
(r = 0.064, P > 0.05; Figure 4).  201 
 202 
Although staining density was diffuse throughout the villous syncytiotrophoblasts, there was 203 
also dense staining localised specifically around fetal vessels in 18 (PRR) and 8 (AGT) of the 204 
50 placenta (Figure 1). The presence of perivascular staining for PRR and AGT was found to 205 
be associated with increased maternal TBARS (Chi-squared P = 0.001 and P = 0.033).  206 
 207 
 208 
 209 
 210 
 211 
 212 
 213 
 214 
 215 
 216 
 217 
 218 
 219 
 220 
 221 
 222 
 223 
 224 
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Discussion 225 
It has been known for nearly 40 years [37] that there is a tissue-based RAS in the 226 
uteroplacental unit, suggesting a locally acting RAS. Our localised staining of the RAS 227 
components to the syncytiotrophoblast is consistent with other very recent results [38]. Our 228 
study demonstrates that the placental RAS may be involved in pre-eclampsia, with raised 229 
AT1R expression, together with the raised AngII concentrations previously reported [15, 16], 230 
contributing to the restricted fetal growth characteristically observed in this syndrome. The 231 
pressor response to AngII is well known to be enhanced before pre-eclampsia is clinically 232 
detectable [39] and is associated with an increased density of AT1Rs [40]. Agonist 233 
autoantibodies to the AT1R are also increased in pre-eclampsia [41].  234 
 235 
The inverse correlation between placental AT1R and GPx3 expression (Figure 3) is 236 
particularly interesting in light of the stimulatory effect of AngII on ROS generation [17]. 237 
The absence of adequate antioxidant protection in pre-eclampsia might enhance the 238 
vasoconstrictor effect of locally-generated AngII. The specific clustering of both the PRR and 239 
AGT around the vessels, in conjunction with elevated measures of oxidative stress (TBARS), 240 
suggests that the RAS may be contributing to the heightened state of oxidative stress in 241 
placental tissue of pre-eclamptic pregnancies. ROS superoxide anion (O2
-) has been 242 
implicated in Ang II-mediated hypertension [42] and experimental data in the non-pregnant 243 
state support the concept that Ang II-mediated hypertension in pregnancy may also be due, in 244 
part, to effects on the oxidative state in vascular-endothelial tissue [43]. 245 
 246 
There is some controversy surrounding the regulation of placental AT1R in pre-eclampsia. 247 
The increase in placental AT1R expression in pre-eclampsia we observed is in agreement 248 
with previous studies in placental [44] and decidual [17] tissue. However, two earlier studies 249 
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reported that the capacity and affinity of AT1R were significantly lower in placentae from 250 
pregnancies complicated by pre-eclampsia and IUGR [45] and in a previous study we also 251 
found no significant increase in placental AT1R expression [26]. It is now well established 252 
from several studies that gradients in gene expression [46] or enzyme activity [8] exist across 253 
the placenta. In our original paper [26], results were reported from biopsies taken within 1cm 254 
of the cord insertion. We have subsequently demonstrated an increase in placental ACE 255 
activity at the periphery [47], where sensitivity of chorionic plate arteries to Ang II is greatest 256 
[48]. In the current investigation, we therefore studied samples collected from 1cm from the 257 
periphery of the placenta.  This adds further weight to the requirement for structured, rather 258 
than random, sampling across the placental disc, with clear reporting of sampling site. 259 
 260 
We have, for the first time, identified a clear relationship between placental AT2R and AGT 261 
expression in pre-eclamptic, but not normotensive pregnancy (Figure 4). The AT2R appears 262 
to function as an ‘antagonist’ of AT1R [49], and is predominantly expressed in fetal tissue 263 
[50]. Ang II binding to AT2Rs increases apoptosis, causes vasodilation and is thought to be 264 
involved in fetal tissue development [51, 52]. Thus, the strong positive associations observed 265 
in the pre-eclamptic placentae between AT2R and AGT may indicate a potential 266 
compensatory mechanism, not activated in normotensive pregnancy.  267 
 268 
The human placenta possesses an autonomous RAS, allowing the local generation of Ang II 269 
and its fragments. Our data suggest that, at term, increased activity in this local system, 270 
particularly evident in the syncytiotrophoblast, may contribute to both pre-eclampsia itself 271 
and the IUGR which frequently accompanies it. We have not addressed the question of 272 
distinguishing between the effects of placentally-generated AngII and fetal systemic AngII.  273 
 274 
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Figure Legends 439 
Figure 1: Immunohistochemical staining of AGT (A1 to A3), PRR (B1 to B3), AT1R (C1 to 440 
C3) and AT2R (D1 to D3) at x200 magnification. Positive staining shown in brown, black 441 
arrows indicate syncytiotrophoblast cells and red arrows show fetal vessels. ATIR expression 442 
was increased in the pre-eclamptic compared to the normotensive control placentae (P < 443 
0.05). 444 
Figure 2:  Scatter plot illustrating the inverse association between AT1R expression in the 445 
placenta, and the birthweight in the pre-eclamptic group (r = -0.529; P = 0.009); not observed 446 
in the controls (r = -0.117; P > 0.05). 447 
Figure 3: Inverse association between the expression of GPx3 and AT1R in the placenta (r = 448 
-0.634; P = 0.006). Placental GPx3 activity was only measured in 10 pre-eclampsia and 10 449 
normotensive control samples. 450 
Figure 4: Scatter plots showing the positive association between the placental AGT and 451 
AT2R expression in pre-eclamptic (r = 0.615; P = 0.002) but not normotensive controls (r = 452 
0.064; P > 0.05).  453 
 454 
 455 
 456 
 457 
 458 
 459 
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Table 1. Details of antibody sources and dilutions. 460 
Antigen Suppler information Concentration 
(mg/mL) 
PRR Sigma Prestige, rabbit 
polyclonal: HPA003156 
1.8 
AGT Sigma Prestige, rabbit 
polyclonal: HPA0031557 
0.26 
AT1R Abcam, mouse momoclonal: 
ab9391 
80 
AT2R Abcam, rabbit polyclonal: 
ab19134 
5.2 
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Table 2: Obstetric data of subject groups. Data are presented as mean ±SD or median [IQR] 471 
as appropriate. *P <0.05, **P < 0.001; more detailed data has been previously published 472 
(Mistry et al 2008). 473 
Parameter Normotensive control 
(n = 27) 
Pre-eclampsia 
(n = 23) 
Gestational age at 
delivery (weeks) 
40 ± 1.1 36.4 ± 3.8*  
Birthweight (kg) 3.55 [3.25, 3.86] 2.92 [1.92, 3.51]* 
Birthweight centiles (%) 45 [23, 67] 35 [2, 87] 
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Table 3: Placental protein expression (H-Score) of AGT, PRR, AT1R, ATT2R and GPx3. *P 488 
< 0.05; #previously published (Mistry et al 2008) and placental GPx3 activity was only 489 
measured in 10 pre-eclampsia and 10 normotensive control samples.  490 
Protein expression 
H-Score (Median [ interquartile range]) 
Normotensive control Pre-eclampsia 
AGT 34 [10,95] 30 [9,60] 
PRR 117 [16,144] 139 [72,187] 
AT1R 40 [10,70] 68 [30,112]* 
AT2R 152 [120,180] 184 [74,220] 
Placental GPx3 
expression (AU) # 
197 [124, 254] 110 [82, 124]* 
 492 
 493 
